Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment
Anita Bakrania1,2,3, Gang Zheng3,4,5, Mamatha Bhat1,2,6,7
1Toronto General Hospital Research Institute, Toronto, ON M5G 2C4, Canada.
Abstract:
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2-9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of improving the safety and efficacy of treatment for HCC. Although remarkable success has been achieved in nanomedicine research, there are unique considerations such as molecular heterogeneity and concomitant liver dysfunction that complicate the translation of nanotheranostics in HCC. This review highlights the progress, challenges, and targeting opportunities in HCC nanomedicine based on the growing literature in recent years.
Insights
Hepatocellular carcinoma (HCC) nanomedicine shows promise for improving treatment safety and efficacy. Challenges like liver dysfunction and tumor heterogeneity require further research for successful nanotheranostic translation.
Area of Science:
- Oncology
- Nanomedicine
- Biotechnology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer death with poor survival rates.
- Current HCC treatments face limitations in effectiveness and safety.
- Nanotechnology offers potential for improved HCC therapy.
Purpose of the Study:
- To review recent advancements in nanomedicine for HCC treatment.
- To identify challenges in translating nanotheranostics for HCC.
- To explore targeting opportunities in HCC nanomedicine.
Main Methods:
- Literature review of recent nanomedicine research in HCC.
- Analysis of progress, challenges, and targeting strategies.
- Focus on nanotheranostics for hepatocellular carcinoma.
Main Results:
- Nanomedicine has achieved significant progress in HCC research.
- Molecular heterogeneity and liver dysfunction are key challenges.
- Various targeting strategies are being explored for HCC nanotheranostics.
Conclusions:
- Nanotheranostics hold promise for HCC treatment but face translation hurdles.
- Addressing tumor heterogeneity and liver dysfunction is crucial.
- Continued research is needed to optimize nanomedicine for HCC.
More Related Videos
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
